Tags

Type your tag names separated by a space and hit enter

Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Optom Vis Sci. 2018 12; 95(12):1149-1154.OV

Abstract

SIGNIFICANCE

We compared the 24-month outcomes of ranibizumab and dexamethasone implants in treatment-naive branch retinal vein occlusion patients. Ranibizumab was effective in improving visual outcomes, whereas the dexamethasone implant was not.

PURPOSE

The aim of this study was to compare the 2-year real-world outcomes of intravitreal ranibizumab with dexamethasone implants in patients with macular edema secondary to branch retinal vein occlusion.

METHODS

The treatment-naive branch retinal vein occlusion patients with macular edema who were treated with intravitreal ranibizumab or dexamethasone implant were included retrospectively. Primary outcome measures were the change in best-corrected visual acuity and central retinal thickness.

RESULTS

Eighty-seven eyes of 87 patients were included. Mean ± SD best-corrected visual acuity in the intravitreal ranibizumab group at baseline and 24 months was 0.64 ± 0.48 and 0.49 ± 0.44 logMAR (P < .05). Mean ± SD best-corrected visual acuity in the intravitreal dexamethasone implant group at baseline and 24 months was 0.98 ± 0.56 and 0.92 ± 0.61 logMAR (P > .05). Mean ± SD central retinal thickness in the intravitreal ranibizumab group at baseline and 24 months was 530 ± 150 and 337 ± 103 μm (P < .05). Mean ± SD central retinal thickness in the intravitreal dexamethasone implant group at baseline and 24 months was 591 ± 113 and 335 ± 99 μm (P < .05). Mean ± SD number of injections at 24 months was 5.6 ± 1.8 in the intravitreal ranibizumab group and 2.7 ± 1.1 in the dexamethasone implant group (P < .0001). Progression in lens opacity was detected in 5.7% of the phakic patients in the intravitreal ranibizumab group and 46.1% of them in the dexamethasone implant group (P < .0001). None of the patients in the intravitreal ranibizumab group and 9 (22.0%) of 41 patients in the dexamethasone implant group showed an increase of more than 10 mmHg in intraocular pressure.

CONCLUSIONS

Ranibizumab was effective in the treatment of macular edema secondary to branch retinal vein occlusion in both visual and anatomical outcomes; however, dexamethasone implant was effective only in anatomical outcomes.

Authors+Show Affiliations

No affiliation info availableBeyoglu Eye Training and Research Hospital, Istanbul, Turkey *abdozkaya@gmail.com.Beyoglu Eye Training and Research Hospital, Istanbul, Turkey *abdozkaya@gmail.com.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

30451802

Citation

Ozkaya, Abdullah, et al. "Ranibizumab Versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes." Optometry and Vision Science : Official Publication of the American Academy of Optometry, vol. 95, no. 12, 2018, pp. 1149-1154.
Ozkaya A, Tarakcioglu HN, Tanir I. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. Optom Vis Sci. 2018;95(12):1149-1154.
Ozkaya, A., Tarakcioglu, H. N., & Tanir, I. (2018). Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. Optometry and Vision Science : Official Publication of the American Academy of Optometry, 95(12), 1149-1154. https://doi.org/10.1097/OPX.0000000000001306
Ozkaya A, Tarakcioglu HN, Tanir I. Ranibizumab Versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. Optom Vis Sci. 2018;95(12):1149-1154. PubMed PMID: 30451802.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. AU - Ozkaya,Abdullah, AU - Tarakcioglu,Hatice Nur, AU - Tanir,Ipek, PY - 2018/11/20/pubmed PY - 2019/9/29/medline PY - 2018/11/20/entrez SP - 1149 EP - 1154 JF - Optometry and vision science : official publication of the American Academy of Optometry JO - Optom Vis Sci VL - 95 IS - 12 N2 - SIGNIFICANCE: We compared the 24-month outcomes of ranibizumab and dexamethasone implants in treatment-naive branch retinal vein occlusion patients. Ranibizumab was effective in improving visual outcomes, whereas the dexamethasone implant was not. PURPOSE: The aim of this study was to compare the 2-year real-world outcomes of intravitreal ranibizumab with dexamethasone implants in patients with macular edema secondary to branch retinal vein occlusion. METHODS: The treatment-naive branch retinal vein occlusion patients with macular edema who were treated with intravitreal ranibizumab or dexamethasone implant were included retrospectively. Primary outcome measures were the change in best-corrected visual acuity and central retinal thickness. RESULTS: Eighty-seven eyes of 87 patients were included. Mean ± SD best-corrected visual acuity in the intravitreal ranibizumab group at baseline and 24 months was 0.64 ± 0.48 and 0.49 ± 0.44 logMAR (P < .05). Mean ± SD best-corrected visual acuity in the intravitreal dexamethasone implant group at baseline and 24 months was 0.98 ± 0.56 and 0.92 ± 0.61 logMAR (P > .05). Mean ± SD central retinal thickness in the intravitreal ranibizumab group at baseline and 24 months was 530 ± 150 and 337 ± 103 μm (P < .05). Mean ± SD central retinal thickness in the intravitreal dexamethasone implant group at baseline and 24 months was 591 ± 113 and 335 ± 99 μm (P < .05). Mean ± SD number of injections at 24 months was 5.6 ± 1.8 in the intravitreal ranibizumab group and 2.7 ± 1.1 in the dexamethasone implant group (P < .0001). Progression in lens opacity was detected in 5.7% of the phakic patients in the intravitreal ranibizumab group and 46.1% of them in the dexamethasone implant group (P < .0001). None of the patients in the intravitreal ranibizumab group and 9 (22.0%) of 41 patients in the dexamethasone implant group showed an increase of more than 10 mmHg in intraocular pressure. CONCLUSIONS: Ranibizumab was effective in the treatment of macular edema secondary to branch retinal vein occlusion in both visual and anatomical outcomes; however, dexamethasone implant was effective only in anatomical outcomes. SN - 1538-9235 UR - https://www.unboundmedicine.com/medline/citation/30451802/Ranibizumab_versus_Dexamethasone_Implant_in_Macular_Edema_Secondary_to_Branch_Retinal_Vein_Occlusion:_Two_year_Outcomes_ L2 - https://doi.org/10.1097/OPX.0000000000001306 DB - PRIME DP - Unbound Medicine ER -